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Summary In a population-based series of 368 children undergoing surgery for medulloblastoma, 304 (83%)
survived to complete a course of radiotherapy. Among those patients who completed radiotherapy, the short-
term survival rates were lower for young children (those aged under 5 years) than for older children, but by 6
years the survival rates were very similar (-35%) for children in both age groups. Higher survival rates were
obtained in the young children where total macroscopic excision of the tumour was achieved. For older
children there was no difference in survival rates between those with total or partial excision, though the
survival rate was lower for those whose surgery was limited to biopsy. In young children radiotherapy dose
had no effect on survival rates. In older children, survival rates were appreciably higher where doses had been
at least 45Gy to the posterior fossa and 30Gy to the spinal cord, and there were also fewer spinal cord
metastases among those who received a higher spinal cord dose. Ninety (30%) of the 304 children also
received chemotherapy as part of their initially planned treatment; a wide variety of protocols was used and
no conclusions could be drawn as to the effects on survival rates.
In the past, medulloblastoma has been generally
regarded as having a very poor prognosis. The 3-
year and 5-year survival rates for children
diagnosed in Great Britain during 1962-70 were
only 25% and 18% respectively (Draper et al.,
1982). Treatment during this period consisted of
surgery, with varying degrees of removal of the
tumour, followed by a course of radiotherapy;
chemotherapy was sometimes used to treat
recurrences. From 1970, at an increasing number of
centres, children were also given chemotherapy as
part of their initial treatment in addition to surgery
and radiotherapy (Bloom, 1979; Marsden &
Steward, 1976), and clinical trials were set up to
study the effect on survival of maintenance
chemotherapy (Berry et al., 1981; Gerosa et al.,
1981). The purpose of the present analysis is to
examine the possible effects on survival of
variations in the initial planned treatment of
childhood medulloblastoma.
Patients and methods
During 1971-77 there were 368 children in Great
Britain notified through the national cancer
registration scheme with a diagnosis of
medulloblastoma which was histologically
confirmed following surgery. Confirmation of
diagnosis and information on treatment and follow-
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up were obtained from the hospitals at which the
children were treated or from their family doctors.
All children who were not already known to have
died, and who were resident in England and Wales
at the time of diagnosis, were "flagged" at the
National Health Service Central Register, so that
any deaths would automatically be notified to us,
and have thus been followed up to the end of 1982.
We have received death certificates for children in
Scotland dying of cancer up to the end of 1982; for
the purpose of the present analysis we have
assumed that children in Scotland not notified to us
as having died, were still alive on 31 December
1982. In the series under review there were 239
boys and 129 girls. At the time of operation, 40 of
the children were aged under 2 years, 88 were aged
2-4, 151 were aged 5-9 and 89 were aged 10-14.
Results
Treatment
Of the 368 children who were ascertained, 47 died
post-operatively without receiving further
treatment. Sixteen further children died before their
radiotherapy could be completed, and another was
withdrawn from radiotherapy by his parents. The
remaining 304 children received a complete course
of radiotherapy. Table I shows the total tumour
dose of radiotherapy to the posterior fossa for these
304 children. Doses varied from 15.5 to 55Gy, with
a tendency to give higher doses during the more
recent years. Although there were children in both
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Table I Total dose to posterior fossa in completed course ofradiotherapy
Total dose (Gy)
<40 40-44 45-49 50+ NR Total
Year ofdiagnosis 1971-74 39 (23%) 36 (21%) 42 (24%) 51 (29%) 5 (3%) 173
1975-77 21 (16%) 23 (18%) 42 (32%) 44 (34%) 1 (1%) 131
Age (years) at diagnosis
0-4 24 (25%) 20 (21%) 33 (34%) 19 (20%) 1 (1%) 97
5-14 36 (17%) 39 (19%) 51 (25%) 76 (37%) 5 (2%) 207
Total 60 (20%) 59 (19%) 84 (28%) 95 (31%) 6 (2%) 304
Table II Total dose ofradiotherapy to spinal cord
Posterior
Age (years) fossa dose Spinal cord dose (Gy)
at diagnosis (Gy) <30 30-34 35+ NR Total
0-4 <45 21 (48%) 11 (25%) 6 (14%) 6 (14%) 44
0-4 45+ 5 (10%) 32 (62%) 10 (19%) 5 (10%) 52
5-14 <45 21(28%) 24 (32%) 11(15%) 19 (25%) 75
5-14 45+ 15(12%) 69(54%)29(23%) 14 (11%) 127
Total 62 (21%) 136 (46%) 56 (19%) 44 (15%) 298
age groups who received doses in the lowest and
highest ranges, there was a tendency for older
children to be given a higher dose. Some of the
children later underwent further radiotherapy for
recurrence of their tumours: this additional
treatment has been excluded from Table I. Table II
shows the distribution of radiotherapy doses to the
spinal cord for children with a known posterior
fossa dose. As with the treatment of the posterior
fossa, younger children tended to be given a lower
dose. A higher spinal cord dose was associated with
a higher posterior fossa dose in children of all ages.
The radiotherapy dose to the whole brain has not
been separately tabulated. Where it was known, this
was the same as the spinal cord dose in 74% of
cases, and in the range between spinal cord and
posterior fossa dose in the remainder.
A summary of the chemotherapy used in the
initial planned treatment of the children who
completed a course of radiotherapy is given in
Table III. A small number of patients were given
chemotherapy during the period between diagnosis
and the completion of radiotherapy, with no further
treatment thereafter. A larger number received
chemotherapy for a period of up to 2 years
following radiotherapy; many of these children had
also received chemotherapy during the period up to
Table III Chemotherapy given to
radiotherapy
children completing
Age (years) at
diagnosis
Chemotherapy 0-4 5-14 Total
None 65 149 214
Before completion ofradiotherapy
only
VCR alone 2 4 6
MTX alone 0 1 1
VCR+MTX 2 1 3
*Post-radiotherapy
VCR alone 2 4 6
VCR+MTX+CCNU 1 5 6
VCR+MTX 5 1 6
VCR+BCNU 6 7 13
VCR+CCNU 9 22 31
VCR+CCNU+PCZ 3 6 9
Other 2 7 9
Total 97 207 304
VCR=vincristine.
MTX=methotrexate.
PCZ=procarbazine.
*Some children in this group also received
chemotherapy before completion of radiotherapy.MEDULLOBLASTOMA: TREATMENT AND SURVIVAL 837
the end of radiotherapy. The "other combinations"
group of Table III includes various combinations of
vincristine, methotrexate, CCNU, procarbazine,
VM26 and DTIC. Some children, including some
who had not previously received chemotherapy,
were given chemotherapy as treatment for
recurrence of their tumours. This chemotherapy has
been excluded from Table III. Thirteen children
whose tumours were diagnosed during 1971-74
were included in a trial of immunotherapy using
killed medulloblastoma vaccine. For the purposes
of Table III and all other analyses presented here,
these children are included in the "no chemo-
therapy" group. There was no significant difference
between the age groups in the proportion of
children receiving chemotherapy.
Survival
The overall five-year survival rate for the 368
surgically treated children in this series was 32%.
The rate was 27% for those diagnosed during
1971-74 and 38% for 1975-77.
Table IV shows the proportions of children who
survived to complete their radiotherapy, classified
Table IV Proportions of children surviving to complete a
course of radiotherapy classified by year of diagnosis, age
and extent of surgery
Radio-
therapy
No radio- started Radio-
therapy but not therapy
Year ofdiagnosis given completed completed Total
1971-74 29 12 173 (81%) 214
1975-77 18 5 131 (85%) 154
Age at diagnosis
(years)
0-4 22 9 97 (76%) 128
5-14 25 8 207 (86%) 240
Extent of surgery
biopsy only 12 3 43 (74%) 58
Subtotal
excision 28 11 177 (82%) 216
Total excision 6 2 81 (91%) 89
Unknown 1 1 3 5
Total 47 17 304 (83%) 368
by year of diagnosis, age and extent of surgery. The
slight increase in more recent years in the
proportion of children completing their
radiotherapy was not statistically significant. The
proportion of children surviving to complete their
radiotherapy was significantly higher among those
aged 5-14 years than in the younger age group
(X2=5.66 on 1 df, P<0.05). The remaining survival
analyses are based on the 304 children who received
a complete course ofradiotherapy.
There was no difference in survival rates between
the sexes. Figure 1 shows the actuarial survival
curves for children aged 0-4 and 5-14 years at
diagnosis. There was a significant difference in 3-
year survival rates between the age groups
(XI=7.76 on 1 df, P<0.01), but the overall
difference between the two survival curves was not
statistically significant (X2=2.97 on 1 df, P>0.05)
and by 6 years from diagnosis the two age groups
had very similar rates.
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Figure 1 Actuarial survival curves for children aged
0-4 years ( ; n=97 and 5-14 (----; n=207) at
diagnosis.
Figure 2 shows the survival curves for children
aged under 5 years classified according to whether
or not total macroscopic excision of their tumour
was achieved. Survival rates in this age group were
significantly higher for patients whose tumours
were totally removed than for those who had
residual tumour present after operation (X2 =4.66
on 1 df, P<0.05). There was no difference in
survival among children aged 5-14 years between
those whose tumours were totally removed and
those whose tumours were only partially removed.
The survival rate for children in this age group who
underwent biopsy alone was significantly lower
than for those who had more extensive surgery
(X2=7.18 on 1 df, P<0.01).
Figure 3 shows the relationship between posterior
fossa radiotherapy dose and survival among
children aged 5-14 years. Survival rates were
signiificantly higher in those who received at least
45Gy to the posterior fossa (X2 = 16.7 on 1 df,838 C.A. STILLER & E.L. LENNOX
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Biopsy (n 14P<0.0001). For children in this age group there Bilopsy (n 14) was also a significant trend towards higher survival
Partial excision (n
= 47) rates with increasing dose of radiotherapy to the
Total excision (n = 34) spinal cord (Figure 4; x2=5.17 on 1 df, P<0.05).
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Figure 2 Actuarial survival curves for children aged
0-4 years at diagnosis, classified according to extent of
surgical excision of tumour.
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Figure 3 Actuarial survival curves for children aged
5-14 years at diagnosis, classified according to
posterior fossa radiotherapy dose.
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Figure 4 Actuarial survival curves for children aged
5-14 years at diagnosis, classified according to spinal
cord radiotherapy dose.
There was no corresponding effect of posterior
fossa or spinal cord dose on survival rates in the
younger age group. Because of the close
correspondence between the doses of radiotherapy
to the whole brain and to the spinal cord, it was
not possible to analyse the effects of doses to these
two fields independently.
Table V summarises the results of significance
tests on the survival curves for children in the two
Table V Effect on survival of extent of surgery (total
excision vs. subtotal excision or biopsy); posterior fossa
dose (>45Gy vs. <45Gy) and spinal cord dose (>30Gy
vs. <30Gy): comparison of results of significance tests (X2
on 1 df).
Age at diagnosis (years) 0-4 5-14
Effect of Allowing for
Surgery PF dose, SC dose 2.78 0.10
PF dose Surgery, SC dose 0.01 8.74*
SC dose Surgery, PF dose 0.00 3.43
PF=Posterior fossa.
SC=Spinal cord.
*P<0.01.
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age groups, analysing the effects of the extent of
surgery, posterior fossa dose, and spinal cord dose.
The overall actuarial rate of occurrence of spinal
cord metastases in our series was 21% at 5 years.
Among children aged 5-14 years the rate was 41%
for those who received spinal cord doses of under
30Gy compared with 14% for those with higher
doses. The difference was statistically significant
(X2 =5.50 on 1 df, P<0.05). When posterior fossa
dose was allowed for, the difference was no longer
significant (X2 =2.59 on 1 df, P>0.1). There was no
evidence of an effect of spinal cord dose on the
incidence of spinal metastases among younger
children.
Figure 5 shows the survival curves for children
classified according to whether they received
chemotherapy as part of their initial planned
treatment. The survival rate was higher among
children who were given chemotherapy, but not
significantly so (X2=2.83 on 1 df, P>0.05). When
age, extent of surgery and posterior fossa
radiotherapy dose were taken into account, there
was no evidence of an effect on survival which
could be attributed to chemotherapy. Because of
the wide variety of combinations of drugs which
were used during the period covered by this study,
it was not possible to assess the effects of individual
chemotherapy regimes.
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Figure 5 Actuarial survival curves for children of all
ages combined, classified according to whether
chemotherapy was included in initial planned
treatment. ( ) chemotherapy; (n =90); (----) no
chemotherapy (n =214).
The neurosurgical centres were divided into 4
groups according to whether the total number of
cases of childhood medulloblastoma treated by
them during 1971-77 was in the range 1-5, 6-10,
11-20 or over 20. There was found to be no
difference in survival rates between the four groups.
The same classification was used for the
radiotherapy centres, and again there was no
difference in survival rates.
Discussion
The present series of children was ascertained from
the national cancer registration scheme, which is
notified of over 90% of all cases of childhood
cancer in Great Britain (Draper et al., 1982); it is
thus population based and nearly complete. The
total number of 304 patients completing their initial
planned course of radiotherapy is considerably
larger than any previously reported in a detailed
study of childhood medulloblastoma. There is
known to be a risk ofmortality for some years after
diagnosis with this tumour; the minimum period of
follow-up in our study is 5 years, with some
patients having been followed up for as long as 12
years after diagnosis. The age distribution of this
series was similar to that of a large series
aggregated from a review of the literature (Choux
et al., 1982) except that ours contained a larger
number of children aged 10 years and over. This
discrepancy may be explained by the fact that many
of the series reviewed were from children's hospitals
and would be expected to contain a preponderance
of younger patients.
The post-operative treatment administered to
individual children with medulloblastoma during
1971-77 was in general not randomly allocated
within a clinical trial. However, a close examination
of the data relating to children treated at particular
centres suggests very strongly that at any centre at
any given time the doses of radiotherapy were
standardised, though with a tendency at some
hospitals for older children to be given higher
doses. It appears that at the great majority of
hospitals at any time chemotherapy was either
included in the initial planned treatment for all
children with medulloblastoma or for none, or was
randomly allocated within clinical trials. Therefore,
although the analyses of survival related to
treatment should be interpreted with some caution,
it seems unlikely that differences in survival rates
between groups of children undergoing different
treatment are attributable to selective bias in the
allocation of treatment to different categories of
patient.
From the results presented above, it is clear that
the short-term prognosis is poorer for children aged
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under 5 years than for older children. However, in
the longer term it appears that the survival rates for
the two age groups are similar, and in the present
series the 6-year survival rates for children who
completed their treatment were 34% for those aged
0-4 years at diagnosis and 35% for those aged 5-14
years. Bloom et al. (1969) also found that long-term
survival rates were similar for patients of all ages
but that deaths tended to occur earlier among
younger patients. The tendency for mortality to be
more concentrated in a short period after diagnosis
among younger patients has also been noted in
children with neuroblastoma, another embryonal
tumour of nervous tissue (Kinnier Wilson &
Draper, 1974; Draper et al., 1982).
In the past total excision of a medulloblastoma
has generally been held to result in higher survival
rates (Choux et al., 1982). Among the children aged
under 5 years in the present series, survival rates
were considerably higher for those who had
undergone total surgical removal of their tumours.
In the older age group the extent of the surgery
appeared to make little difference to survival rates,
except that the survival rate for patients whose
tumours were merely biopsied was lower. In 13/43
children whose surgery was limited to biopsy it was
explicitly stated that the tumour was inoperable,
and this presumably also applied in some other
cases. Where excision of the tumour was attempted,
many factors may have influenced the degree of
removal, including tumour size and the extent of
local spread. In particular no tumour involving the
brain stem will have been totally removed. Brain
stem involvement has been previously reported as
an indicator of poor prognosis (Bloom et al., 1969),
and the 5-year survival rate in our series was indeed
extremely low (1/13, 8%). However, it appears very
likely that we failed to ascertain many cases of
brain stem involvement; in our series 13/304 (4%)
such cases were reported, whereas in a recent study
of childhood medulloblastoma by the United
Kingdom Children's Cancer Study Group, brain
stem involvement was noted in 7/49 (14%) (C.C.
Bailey, personal communication).
There was a clear advantage associated with a
radiotherapy dose of at least 45Gy to the posterior
fossa in children aged 5 years and over, but higher
doses apparently did not improve the prospects for
survival for younger children. In a report on
children aged under 5 years with brain tumours,
Deutsch (1982) found very few survivors who
received a dose of less than 40Gy, but it is
impossible to deduce the dose given to the patients
with medulloblastoma in his series and for some
patients the period of follow-up was very short. We
found a tendency for higher doses to the posterior
fossa to be associated with higher spinal cord doses,
and this fact makes it difficult to determine the
effect on survival of the spinal cord radiotherapy
dose. Nevertheless when allowance was made for
the effect of posterior fossa dose, the higher
survival rate and lower incidence of spinal cord
metastases amongst the older age group who
received at least 30Gy to the spinal cord both
approached statistical significance.
There appeared to be little influence of
chemotherapy on survival rates in our series but
certain combinations of drugs may have a
beneficial effect which it was not possible to detect
in the present study because of the small number of
children treated according to any one protocol.
There is as yet no clear consensus amongst workers
using standardised protocols on the effects of
chemotherapy on survival in patients with medullo-
blastoma. Some studies have shown higher survival
rates to be associated with chemotherapy, at least
in some subgroups of patients (Berry et al., 1981;
Bloom et al., 1969; Bloom, 1982a,b), while in
others there has so far been no demonstrable
benefit derived from the use of chemotherapy
(Evans et al., 1979; van Eys et al., 1981).
In the great majority of children who completed
their treatment for medulloblastoma and
subsequently died, death was caused by the tumour,
though a small number of exceptions has been
identified. Two children, who had both undergone
maintenance chemotherapy with BCNU, died with
fibrosing changes in the lungs at 30 and 44 months
after diagnosis, and were apparently tumour-free at
the time of death. The fatal lung disease in these
children was attributed to the use of BCNU (Bailey
et al., 1978) and this drug has since been widely
demonstrated to cause pulmonary fibrosis. One
child died from progressive cerebral necrosis of
unknown cause 39 months after the diagnosis of
medulloblastoma, and was found to be tumour-free
at post mortem. Another patient developed acute
undifferentiated leukaemia and died 27 months
after diagnosis of the original tumour. There were
no other cases of second primary neoplasms in the
present series. However, in a series of childhood
medulloblastoma survivors treated in earlier years
(1940 onwards) and with a correspondingly longer
period of follow-up, cases of basal cell carcinoma,
osteosarcoma, fibrosarcoma, meningioma and
carcinoma of the colon have been observed
(Kingston et al., in preparation). In a study of 58
patients who died more than 5 years after treatment
of childhood medulloblastoma during 1940-70, 48
(83%) deaths were directly attributable to the
tumour, 5 were due to second primary neoplasms
and 5 were due to other causes including infections
and accidents (J.E. Kingston, personal
communication). In the present series there have soMEDULLOBLASTOMA: TREATMENT AND SURVIVAL 841
far been 14 patients who died over five years after
diagnosis, with recurrent tumour being the
underlying cause of death in all cases.
In conclusion, the improvement in survival rates
for childhood medulloblastoma during the period
under review may be largely attributed to the
effects of higher doses of radiotherapy on older
children. Any definitive statement on the
advantages of chemotherapy must await the
analysis and publication of the several recent and
current clinical trials for this tumour. The only
factor which appeared to influence the prognosis
for younger children was the extent of surgical
removal of the tumour. With recent advances in
neurosurgical techniques, the possibility that more
extensive surgery may compensate for lower doses
of radiotherapy could be explored in a prospective
study. Effective treatment of childhood medullo-
blastoma may then be achieved without the long
term complications associated with high doses of
radiation.
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